Abstract
As in many other countries, contacts traced through the NHS Test and Trace scheme in England are asked to quarantine for 14 days from the day they were exposed to the index case, to minimise the risk for pre-symptomatic and asymptomatic onward transmission. However, the standard quarantine period could be reduced for negative contacts if combined with PCR testing to assess SARS-CoV-2 negative status.
We used a simulation model for contact tracing, accounting for the incubation period, infectivity profile, and time-varying probability of detection by PCR to estimate the transmission potential of traced contacts averted by different durations of quarantine and number of tests. We also investigated the effect of reducing test and tracing delays, and reduced adherence to quarantine guidance.
Assuming perfect adherence to quarantine and self-isolation upon symptom onset, we find that a negative PCR test on day 10 of the quarantine would reduce the transmission potential from secondary cases similarly to the current 14 day quarantine rule: 68% (50% UI: 37, 100%) vs. 70% (50% UI: 38, 90%), respectively. A PCR test taken on the day of tracing would avert 57% of transmission potential on average (50% UI: 25%, 81%). Halving observed delays from having a test to the tracing of contacts to an average of 2 days reduces the pre-tracing transmission potential to 11% (50% UI: 2%, 27%) compared to 29% (50% UI: 8, 62%) with an average 4 day delay. Poor adherence greatly reduces the transmission potential averted (7% (50% UI: 4, 90%) using a reported 10% adherence rate in the UK for a 14 day quarantine).
PCR testing may allow for a reduction in the duration of quarantine of traced contacts from 14 to 10 days without increasing the risk for onward transmission. Testing immediately after tracing could further reduce quarantine but would slightly increase the transmission risk. Multiple testing provided little additional benefit. Reducing delays and increasing adherence are likely to increase the ability of test, trace, isolate to reduce transmission above that of the introduction of PCR testing.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was partly funded by the National Institute for Health Research (NIHR) (Billy Quilty is funded by 16/137/109 & 16/136/46) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care. This research has been funded by UK Research and Innovation - MC_PC_19065 - Covid 19: Understanding the dynamics and drivers of the COVID-19 epidemic using real-time outbreak analytics (Samuel Clifford, W John Edmunds). This research was partly funded by the Wellcome Trust (Sir Henry Dale Fellowship: 208812/Z/17/Z, Stefan Flasche and Samuel Clifford; 206250/Z/17/Z, Adam J Kucharski). This project has received funding from the European Union's Horizon 2020 research and innovation programme - project EpiPose (W John Edmunds). The authors declare no conflicts of interest. The following funding sources are acknowledged as providing funding for the working group authors. Alan Turing Institute (AE). BBSRC LIDP (BB/M009513/1: DS). This research was partly funded by the Bill & Melinda Gates Foundation (INV-001754: MQ; INV-003174: KP, MJ, YL; NTD Modelling Consortium OPP1184344: CABP, GFM; OPP1180644: SRP; OPP1183986: ESN; OPP1191821: KO'R, MA). BMGF (OPP1157270: KA). DFID/Wellcome Trust (Epidemic Preparedness Coronavirus research programme 221303/Z/20/Z: CABP, KvZ). DTRA (HDTRA1-18-1-0051: JWR). Elrha R2HC/UK DFID/Wellcome Trust/This research was partly funded by the National Institute for Health Research (NIHR) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care (KvZ). ERC Starting Grant (#757699: JCE, MQ, RMGJH). This project has received funding from the European Union's Horizon 2020 research and innovation programme - project EpiPose (101003688: KP, MJ, PK, RCB, YL). This research was partly funded by the Global Challenges Research Fund (GCRF) project 'RECAP' managed through RCUK and ESRC (ES/P010873/1: AG, CIJ, TJ). HDR UK (MR/S003975/1: RME). Nakajima Foundation (AE). NIHR (16/137/109: CD, FYS, MJ, YL; Health Protection Research Unit for Immunisation NIHR200929: NGD; Health Protection Research Unit for Modelling Methodology HPRU-2012-10096: TJ; NIHR200929: MJ; PR-OD-1017-20002: AR). Royal Society (Dorothy Hodgkin Fellowship: RL; RP\EA\180004: PK). UK DHSC/UK Aid/NIHR (ITCRZ 03010: HPG). UK MRC (LID DTP MR/N013638/1: GRGL, QJL; MC_PC_19065 - Covid 19: Understanding the dynamics and drivers of the COVID-19 epidemic using real-time outbreak analytics: AG, NGD, RME, TJ, YL; MR/P014658/1: GMK). Authors of this research receive funding from UK Public Health Rapid Support Team funded by the United Kingdom Department of Health and Social Care (TJ). Wellcome Trust (206250/Z/17/Z: TWR; 206471/Z/17/Z: OJB; 210758/Z/18/Z: JDM, JH, KS, NIB, SA, SFunk, SRM). No funding (AKD, AMF, CJVA, DCT, KEA, SH, YWDC).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data used for this modelling work is provided to the public by the UK Department of Health and Social Care from the NHS' Test and Trace programme.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The following authors were part of the Centre for Mathematical Modelling of Infectious Disease COVID-19 Working Group. Each contributed in processing, cleaning and interpretation of data, interpreted findings, contributed to the manuscript, and approved the work for publication: Akira Endo, David Simons, Kaja Abbas, Desmond Yung-Wai Chan, Sophie R Meakin, Sam Abbott, James W Rudge, Kathleen O’Reilly, James D Munday, Graham Medley, Rosalind M Eggo, Nikos I Bosse, Emily S Nightingale, Charlie Diamond, Joel Hellewell, Yang Liu, Jon C Emery, Alicia Rosello, Thibaut Jombart, Petra Klepac, Megan Auzenbergs, Quentin J Leclerc, Rosanna C Barnard, Hamish P Gibbs, Amy Gimma, Stéphane Hué, Katherine E. Atkins, Georgia R Gore-Langton, C Julian Villabona-Arenas, Rein M G J Houben, Nicholas G. Davies, Kevin van Zandvoort, Arminder K Deol, Damien C Tully, Yung-Wai Desmond Chan, Simon R Procter, Katharine Sherratt, Gwenan M Knight, Rachel Lowe, Carl A B Pearson, Mark Jit, Christopher I Jarvis, Matthew Quaife, Timothy W Russell, Fiona Yueqian Sun, Sebastian Funk, Kiesha Prem, Oliver Brady, Sam Abbott, Anna M Foss.
Updated data on delays in test and trace system and moved away from combinations of first and second tests to considering testing on initial tracing and at end of quarantine period. All results updated.
Data Availability
Model code is available at https://github.com/cmmid/pcr_track_trace